Provectus CEO reports 2024 note conversion at $2.862 into Series D‑1

Rhea-AI Filing Summary

Provectus Biopharmaceuticals (PVCT) CEO and director reported a non-cash conversion on 10/16/2025. An 8% unsecured convertible promissory note issued in 2024 converted into 18,880 shares of Series D-1 Convertible Preferred Stock at a conversion price of $2.862 per preferred share. Each preferred share is convertible into 10 common shares, equating to 188,800 underlying common shares. The Series D-1 Preferred will automatically convert into common stock on June 20, 2026, unless converted earlier.

Insights

Equity capital markets analyst

Routine insider conversion; administrative, not thesis-changing.

The filing records a conversion of an 8% 2024 note into 18,880 Series D-1 preferred shares at $2.862 per share on 10/16/2025. By terms, each preferred is convertible into 10 common shares, implying 188,800 underlying common. This is a non-cash, structural change in the holder’s form of ownership.

The Series D-1 preferred automatically converts into common on June 20, 2026 unless converted earlier. Actual market impact depends on future conversion or sale decisions by the holder as permitted by applicable rules.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pershing Edward

(Last) (First) (Middle)

800 S. GAY STREET,

SUITE 1610

(Street)

KNOXVILLE TN 37929

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
10/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
8% Unsecured Convertible Promissory Note	$2.862	10/16/2025		M			$50,000	10/16/2024	10/16/2025	Series D-1 Convertible Preferred Stock(3)(4)	18,880	$0	$1,095,000	D
Series D-1 Convertible Preferred Stock	(1)	10/16/2025		M		18,880		10/16/2025	(2)	Common Stock	188,800	$0	2,503,379	D

Explanation of Responses:

1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").

2. The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

3. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2024 Note") at any time while the 2024 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2024 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2024 Note. The 2024 Note was issued pursuant to the Issuer's 2024 Financing.

4. On October 16, 2025, the 2024 Note was converted into 18,880 shares of Series D-1 Preferred Stock.

	/s/ Edward Pershing	10/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did PVCT disclose in this Form 4?

A conversion of an 8% 2024 unsecured convertible promissory note into 18,880 Series D-1 preferred shares on 10/16/2025.

What is the conversion price for the Series D-1 Preferred in PVCT's filing?

The note converted into Series D-1 Preferred at $2.862 per preferred share.

How many PVCT common shares are underlying the new preferred shares?

Each preferred converts into 10 common shares, totaling 188,800 underlying common shares.

When will the PVCT Series D-1 Preferred automatically convert into common stock?

On June 20, 2026, unless converted earlier under the terms of the designation.

Who reported the transaction in PVCT's Form 4 and in what capacity?

The company’s CEO and director reported the transaction, with ownership shown as direct.